Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk's North American head Jakob Riis to leave

He will be replaced by Doug Langa

Novo Nordisk Jakob Riis FalckNovo Nordisk's head of North America Operations and president of Novo Nordisk Inc Jakob Riis has resigned.

He will remain with the Danish pharma company for a transitional period, ahead of joining Copenhagen-based health and safety services company Falck as president and CEO on 1 May.

Riis (pictured) joined Novo in 1996 and spent 10 years as the firm's senior vice president of global marketing, during which he took on additional responsibilities in China and the Pacific region.

However, he only held his US role for seven months, and it will now by filled by Dough Langa, who currently serves as its US senior vice president for market access.

Göran Ando, chairman of Novo's board of directors, said: "We are of course sad to see Jakob Riis leave. He has done a great job throughout his career in Novo Nordisk, and we wish him all the best. 

"We welcome Doug Langa as our new head of North America operations. Doug's experience in the US pharmaceutical market, his leadership skills and expertise in the area of market access make him the natural successor to Jakob Riis."

Langa joined Novo in 2011 as senior director, managed markets, from GlaxoSmithKline where he was senior director of payer marketing and prior to that spent the majority of his career at Johnson & Johnson.

2nd March 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics